2nd Cardiac Safety Conference
|Event Date/Time: Dec 03, 2007||End Date/Time: Dec 04, 2007|
In addition, recent concerns involving certain COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) have highlighted the need for broader cardiac safety surveillance and cardiac risk management programmes, extending well beyond regulatory approval into the post-marketing period. These concerns have now triggered further regulatory reviews of the drug development process and are expected to introduce additional requirements to the drug approval process and the post-marketing commitments from drug manufacturers.
This programme will review and address the above cardiac safety topics and will bring academic, regulatory and industry experts together to exchange ideas and share information with the audience.